KRAS and colorectal carcinoma: However, the efficacy of sotorasib and other KRAS<sup>G12C</sup> inhibitors is limited by intrinsic resistance in colorectal cancer (CRC) and by the rapid emergence of acquired resistance in all treated tumors.